Clinical Trial

The Intestinal Microbiome in Triple Negative Breast Cancer Treated with Immunotherapy

Study acronym: IMPACT
Recruiting
View on ClinicalTrials.gov →
Summary
This study will determine how the intestinal microbiome differs between patients with obesity and early triple-negative breast cancer who achieve a pathologic complete response from preoperative anti-PD-1 immunotherapy (pembrolizumab) versus patients who do not.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-15.
Trial Details
NCT Number NCT06318507
Lead Sponsor Pennington Biomedical Research Center
Conditions Breast Neoplasms
Enrollment 25 participants
Start Date 2024-03-11
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-02-17